FMW Stock Overview A late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and viral-induced acute respiratory distress syndrome (ARDS). More details
Rewards Risk Analysis + 1 more risk
See All Risk Checks Capture your thoughts, links and company narrative
Price History & Performance
Summary of share price highs, lows and changes for Veru Historical stock prices Current Share Price US$0.62 52 Week High US$1.75 52 Week Low US$0.34 Beta -0.55 1 Month Change -6.62% 3 Month Change -10.58% 1 Year Change -4.21% 3 Year Change -88.15% 5 Year Change -77.00% Change since IPO -67.93%
Recent News & Updates
Veru Inc. Auditor Raises 'Going Concern' Doubt Dec 18
New minor risk - Market cap size Nov 13
Veru Inc. Announces Meta-Analysis of Body Composition Data from Older Patients with Obesity Which Supports Potential for Enobosarm to Optimize Weight Loss At Obesityweek Nov 05
Veru Receives Notification from The Nasdaq Stock Market Aug 31
Third quarter 2024 earnings released: US$0.075 loss per share (vs US$0.075 loss in 3Q 2023) Aug 09
Veru Inc. to Report Q3, 2024 Results on Aug 08, 2024 Aug 01 See more updates
Veru Inc. Auditor Raises 'Going Concern' Doubt Dec 18
New minor risk - Market cap size Nov 13
Veru Inc. Announces Meta-Analysis of Body Composition Data from Older Patients with Obesity Which Supports Potential for Enobosarm to Optimize Weight Loss At Obesityweek Nov 05
Veru Receives Notification from The Nasdaq Stock Market Aug 31
Third quarter 2024 earnings released: US$0.075 loss per share (vs US$0.075 loss in 3Q 2023) Aug 09
Veru Inc. to Report Q3, 2024 Results on Aug 08, 2024 Aug 01
New major risk - Financial position Jul 01
Veru Inc. to Present an Update of Veru's Phase 2B Clinical Program of Enobosarm to Augment Fat Loss and to Avoid Muscle Loss When Combined with GLP-1 Drugs for Weight Loss At the Jefferies Global Healthcare Conference May 24
Chairman recently sold €227k worth of stock May 20
High number of new and inexperienced directors May 15
Veru Inc. to Report Q2, 2024 Results on May 08, 2024 May 03
Veru Inc. Enrolls First Patients in Phase 2b Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss Apr 30
Veru Inc. Appoints Louis Aronne as Chief Medical Advisor and A Member of the Scientific Advisory Board Mar 12
Veru Receives a Notification Letter from the Listing Qualifications Department of the Nasdaq Stock Market Feb 29
Veru Inc. Announces New Scientific Advisory Board for Its Enobosarm Program for High Quality Weight Loss Feb 20 Veru Inc. announced delayed 10-Q filing Feb 16
Veru Inc. Announces U.S. Food and Drug Administration Clearance of Investigational New Drug Application for its Phase 2b Clinical Study Feb 07
Veru Receives Non-Compliance Notice From Nasdaq Jan 28 Veru Inc., Annual General Meeting, Mar 26, 2024
Veru Inc. to Report Q1, 2024 Results on Feb 08, 2024 Jan 26
Veru Submits IND Application to FDA for the Development of Enobosarm to Prevent Muscle Loss While Augmenting Fat Loss in Combination with Glp-1 Drugs for Weight Loss Jan 08
New major risk - Shareholder dilution Dec 17 Veru Inc. has completed a Follow-on Equity Offering in the amount of $33 million. Dec 16
Veru Inc. has completed a Follow-on Equity Offering in the amount of $33 million.
Third quarter 2023 earnings released: US$0.075 loss per share (vs US$0.28 loss in 3Q 2022) Nov 19
Veru Inc. Reports Muscle Data from 5 Clinical Studies of Enobosarm Oct 05
Veru Reaches Agreement with FDA on New Phase 3 Clinical Trial for Sabizabulin for Broader Indication Sep 27
Veru Inc. Announces Clinical Data from Its Discontinued Phase 3 ARTEST Clinical Trial of Enobosarm Monotherapy Sep 12
New major risk - Financial position Aug 11
Third quarter 2023 earnings released: EPS: US$0.072 (vs US$0.28 loss in 3Q 2022) Aug 11
New minor risk - Market cap size Aug 09
Veru Inc. to Report Q3, 2023 Results on Aug 10, 2023 Aug 04
High number of new and inexperienced directors Jul 02
Veru Inc.(NasdaqCM:VERU) dropped from Russell 2000 Dynamic Index Jun 25
Veru Announces Executive Appointments Jun 02
Second quarter 2023 earnings released: US$0.48 loss per share (vs US$0.18 loss in 2Q 2022) May 12 Veru Inc. announced that it expects to receive $100 million in funding from Lincoln Park Capital, LLC
Veru Reaches Agreement with FDA on Confirmatory Phase 3 Clinical Trial for Sabizabulin Treatment of Hospitalized COVID-19 Adult Patients at High Risk for ARDS May 06
First quarter 2023 earnings released: US$0.46 loss per share (vs US$0.08 loss in 1Q 2022) Feb 10
Veru Inc., Annual General Meeting, Mar 28, 2023 Jan 28
Veru Inc. to Report Q1, 2023 Results on Feb 09, 2023 Jan 27
Bragar Eagel & Squire, P.C. Announces Class Action Lawsuit Against Veru Inc Jan 24
Veru Inc. Appoints David D. Ho as Chairman of Its Scientific Advisory Board Jan 11
Wolf Haldenstein Adler Freeman & Herz LLP Announces Securities Class Action Lawsuit Against Veru Inc Dec 07
Full year 2022 earnings released: US$1.05 loss per share (vs US$0.097 profit in FY 2021) Dec 06
Veru Inc. Provides Update on FDA Advisory Committee Meeting Regarding Emergency Use Authorization of Sabizabulin to Treat Hospitalized COVID-19 Patients at High Risk for Acute Respiratory Distress Syndrome Nov 10
Veru Inc. Announces Late-Breaker Oral Presentation of Sabizabulin Treatment for Hospitalized Adults with Covid-19 on Supplemental Oxygen At Infectious Disease Week 2022 Oct 25
Veru Inc. to Present Late-Breaker Oral Presentation of Sabizabulin Treatment for Hospitalized Adults with Covid-19 on Supplemental Oxygen At Infectious Disease Week 2022 Oct 14
Veru Inc. Receives Expedited Provisional Registration Regulatory Pathway for Sabizabulin Treatment in Hospitalized COVID-19 Patients by Australia’s Therapeutic Goods Administration Aug 23
Veru Inc. Appoints Jason Davies as Executive Vice President General Manager of Europe, the Middle East and Africa, Latin America, and Asia Pacific Aug 20
Third quarter 2022 earnings released: US$0.28 loss per share (vs US$0.034 loss in 3Q 2021) Aug 12
Veru Inc. to Report Q3, 2022 Results on Aug 11, 2022 Jul 29
Uk’S Medicines and Healthcare Products Regulatory Agency (Mhra) Supports Expedited Review of Marketing Authorization Application for Sabizabulin Treatment in Hospitalized Covid-19 Patients of Veru Inc Jul 27
Veru Announces New England Journal of Medicine Evidence Publication of Phase 3 Clinical Trial Results Demonstrating That Sabizabulin Treatment Significantly Reduced Deaths in High-Risk Hospitalized Covid-19 Patients Jul 07
Veru Submits Emergency Use Authorization Application to U.S. FDA for Sabizabulin, Its Novel, Oral Antiviral and Anti-Inflammatory Drug Candidate for Hospitalized COVID-19 Patients At High Risk for ARDS Jun 08
Veru Announces Presentation of Final Positive Phase 1b/2 Clinical Trial Results for Sabizabulin in Metastatic Castration Resistant Prostate Cancer at the 2022 American Society of Clinical Oncology Annual Meeting Jun 07
Veru Inc. Appoints Joel Batten as Executive Vice President and Head of Its U.S. Infectious Disease Franchise, Effective May 23, 2022 May 19
Second quarter 2022 earnings released: US$0.18 loss per share (vs US$0.038 loss in 2Q 2021) May 13
FDA Has Grants Veru Inc.'s Pre-Emergency Use Authorization (EUA) Meeting Date for Positive Sabizabulin Phase 3 COVID-19 Study May 04
Veru Inc. Announces Results from Randomized Placebo-Controlled Phase 2 Study of Oral Sabizabulin Apr 26
Veru Inc.'s Novel COVID-19 Drug Candidate Reduces Deaths by 55% in Hospitalized Patients in Interim Analysis of Phase 3 Study Apr 12
Veru Inc. Announces the Presentation of Updated Data from the Phase 1B/2 Sabizabulin Study in Men with Metastatic Castration Resistant Prostate Cancer At the 2022 ASCO Genitourinary Cancers Symposium Feb 18
Veru Inc. Reports That Independent Data Monitoring Committee for the Phase 3 Sabizabulin COVID-19 Clinical Study Recommends Continuing Study as Planned Feb 15
First quarter 2022 earnings: EPS in line with expectations, revenues disappoint Feb 10
Investor sentiment improved over the past week Feb 04
Veru Inc. Announces FDA Grant of Fast Track Designation for Sabizabulin for the Treatment of Hospitalized COVID-19 Patients At High Risk for Acute Respiratory Distress Syndrome Feb 01
Veru Inc., Annual General Meeting, Mar 29, 2022 Jan 30
Veru Inc., Annual General Meeting, Mar 29, 2022 Jan 29
Investor sentiment improved over the past week Jan 13
Veru Inc. Announces FDA Grant of Fast Track Designation for Enobosarm for the Treatment of AR+ ER+ HER2- Metastatic Breast Cancer Jan 12
Veru Inc. Announces FDA Approval of ENTADFI Dec 15
Veru Inc. Announces Presentation of Preclinical Evidence Supporting the Therapeutic Benefit of Enobosarm Alone or in Synergistic Combination with a CDK4/6 Inhibitor Against Palbociclib Resistant Metastatic Breast Cancer at the 2021 San Antonio Breast Cancer Symposium Dec 09
Full year 2021 earnings: EPS in line with expectations, revenues disappoint Dec 04
No longer forecast to breakeven Nov 24
Forecast to breakeven in 2021 Sep 23
Veru Announces Positive Updated Data from Phase 1B/2 Sabizabulin Study in Men with Metastatic Castration Resistant Prostate Cancer Sep 21
Third quarter 2021 earnings released: US$0.034 loss per share (vs US$0.045 loss in 3Q 2020) Aug 14
Veru Inc. Announces Enrolls First Patient in Phase 3 Veracity Clinical Trial of Sabizabulin in Metastatic Castration Resistant and Androgen Receptor Targeting Agent Resistant Prostate Cancer Jun 26
Vice Chairman & Chief Corporate Officer recently sold €689k worth of stock Jun 22
Veru Inc. Enrolls First Patient in Phase 2 Clinical Trial of VERU-100, Novel Long-acting GnRH Antagonist Decapeptide Injection Formulation Jun 11 Shareholder Returns FMW DE Personal Products DE Market 7D -10.1% -1.5% -1.6% 1Y -4.2% -7.2% 6.8%
See full shareholder returns
Return vs Market: FMW underperformed the German Market which returned 6.8% over the past year.
Price Volatility Is FMW's price volatile compared to industry and market? FMW volatility FMW Average Weekly Movement 9.5% Personal Products Industry Average Movement 3.7% Market Average Movement 4.9% 10% most volatile stocks in DE Market 11.6% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: FMW's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: FMW's weekly volatility has decreased from 15% to 9% over the past year, but is still higher than 75% of German stocks.
About the Company Veru Inc., a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and viral-induced acute respiratory distress syndrome (ARDS). Its marketed products comprise FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections. The company’s development program includes enobosarm, a selective androgen receptor modulator for treatment of augment fat loss and to prevent muscle loss in sarcopenic obese and overweight elderly patients; Enobosarm, an oral selective androgen receptor modulator for the treatment of AR+ ER+ HER2- metastatic breast cancer; and sabizabulin, a microtubule disruptor for the treatment of hospitalized patients with viral lung infection at high risk for viral induced ARDS and death.
Show more Veru Inc. Fundamentals Summary How do Veru's earnings and revenue compare to its market cap? FMW fundamental statistics Market cap €88.48m Earnings (TTM ) -€36.36m Revenue (TTM ) €16.24m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) FMW income statement (TTM ) Revenue US$16.89m Cost of Revenue US$11.03m Gross Profit US$5.85m Other Expenses US$43.66m Earnings -US$37.80m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -0.26 Gross Margin 34.67% Net Profit Margin -223.86% Debt/Equity Ratio 30.6%
How did FMW perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/25 05:54 End of Day Share Price 2024/12/23 00:00 Earnings 2024/09/30 Annual Earnings 2024/09/30
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Veru Inc. is covered by 12 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution William Wood B. Riley Securities, Inc. Brandon Folkes Cantor Fitzgerald & Co. Yi Chen H.C. Wainwright & Co.
Show 9 more analysts 
